Hepta Medical is a MedTech startup developing an innovative thermal ablation device to treat early-stage lung cancer.

Using temperature sensors and advanced imaging, the system can replace surgical techniques by locally monitoring temperature to better control the size of the ablation zone, ultimately offering a safer, less invasive, and more effective treatment for patients.

After raising over €2M in seed funding and completing a €7M Series A round, Hepta Medical is finalizing its prototyping phase, and the device is already in preclinical testing. The system is fully functional, and the company is launching a comprehensive research program to predict lesion morphology.

Over the next 12 months, Hepta Medical’s goal is to bring the first version of the device to market in the United States.

Hepta Medical has also been recognized with both the Jury Prize and the Public Prize at the 2024 SNITEM Innovative Medical Device Startup Competition (SNITEM is the leading professional organization representing the medical device industry in France).

More information can be found in this detailed 3-minute video: HEPTA Presentation - SNITEM